|
[1]
|
Anderson, W.J. and Doyle, L.A. (2021) Updates from the 2020 World Health Organization Classification of Soft Tissue and Bone Tumours. Histopathology, 78, 644-657. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Tsai, J.W., Lee, J.C., Hsieh, T.H., et al. (2022) Adult NTRK-Rearranged Spindle Cell Neoplasms of the Viscera: With an Emphasis on Rare Locations and Heterologous Elements. Modern Pathology, 35, 911-921. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Ghigna, M.R., Thomas, D.E. and Montperville, V. (2021) Mediastinal Tumours and Pseudo-Tumours: A Comprehensive Review with Emphasis on Multidisciplinary Approach. European Respiratory Review, 30, 200309. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Sbaraglia, M., Bellan, E. and Deitos, A.P. (2021) The 2020 WHO Classification of Soft Tissue Tumours: News and Perspectives. Pathologica, 113, 70-84. [Google Scholar] [CrossRef]
|
|
[5]
|
Cocco, E., Scaltaiti, M. and Driloon, A. (2018) NTRK Fusion-Positive Cancers and TRK Inhibitor Therapy. Nature Reviews Clinical Oncology, 15, 731-747. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Agaram, N.P., Zhang, L., Sung, Y.-S., et al. (2016) Recurrent NTRK1 Gene Fusions Define a Novel Subset of Locally Aggressive Lipofibromatosis-Like Neural Tumors. American Journal of Surgical Pathology, 40, 1407-1416. [Google Scholar] [CrossRef]
|
|
[7]
|
Tauziede-Espariat, A., Duchesne, M., Baud, J., et al. (2023) NTRK-Rearranged Spindle Cell Neoplasms Are Ubiquitous Tumours of Myofibroblastic Lineage with a Distinct Methylation Class. Histopathology, 82, 596-607. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Hung, Y.P., Fletcher, C.D.M. and Hornick, J.L. (2018) Evaluation of Pan-TRK Immunohistochemistry in Infantile Fibrosarcoma, Lipofibromatosis-Like Neural Tumour and Histological Mimics. Histopathology, 73, 634-644. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Hechtman, J., Benayed, R., Hyman, D., et al. (2017) Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions. American Journal of Surgical Pathology, 41, 1547-1551. [Google Scholar] [CrossRef]
|
|
[10]
|
Yin, L., Shi, C., He, X., et al. (2023) NTRK-Rearranged Spindle Cell Neoplasms: A Clinicopathological and Molecular Study of 13 Cases with Peculiar Characteristics at One of the Largest Institutions in China. Pathology, 55, 362-374. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Suurmeijer, A.J.H., Dickson, B.C., Swanson, D., et al. (2018) A Novel Group of Spindle Cell Tumors Defined by S100 and CD34 Co-Expression Shows Recurrent Fusions Involving RAF1, BRAF, and NTRK1/2 Genes. Genes Chromosomes Cancer, 57, 611-621. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Yasui, N., Yoshida, A., Kawamoto, H., et al. (2014) Clinicopathologic Analysis of Spindle Cell/Sclerosing Rhabdomyosarcoma. Pediatric Blood & Cancer, 62, 1011-1016. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Hong, D.S., Dubois, S.G., Kummar, S., et al. (2020) Larotrectinib in Patients with TRK Fusion-Positive Solid Tumours: A Pooled Analysis of Three Phase 1/2 Clinical Trials. The Lancet Oncology, 21, 531-540. [Google Scholar] [CrossRef]
|
|
[14]
|
Drilon, A., Laetsch, T.W., Kummar, S., et al. (2018) Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. The New England Journal of Medicine, 378, 731-739. [Google Scholar] [CrossRef]
|
|
[15]
|
Doebele, R.C., Drilon, A., Pazares, L., et al. (2020) Entrectinib in Patients with Advanced or Metastatic NTRK Fusion-Positive Solid Tumours: Integrated Analysis of Three Phase 1-2 Trials. The Lancet Oncology, 21, 271-282. [Google Scholar] [CrossRef]
|